Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC

被引：0
|
作者：
Kian, W. [1 ,2 ]
Roisman, L. C. [3 ]
Dudnik, J. [1 ,2 ]
Chernomordikov, L. [1 ,2 ]
Allen, A. M. [3 ]
Corn, B. [4 ]
Dudnik, E. [5 ]
Rosenberg, S. K. [6 ]
Zemel, M. [1 ,2 ]
Lavrenkov, K. [1 ,2 ]
Peled, N. [3 ]
机构：
[1] Ben Gurion Univ Negev, Legacy Heritage Ctr, Beer Sheva, Israel
[2] Ben Gurion Univ Negev, Dr Larry Norton Inst, Beer Sheva, Israel
[3] Shaare Zedek Med Ctr, Inst Oncol, Jerusalem, Israel
[4] Davidoff Canc Ctr, Rabin Med Ctr, Thorac Canc Unit, Petah Tiqwa, Israel
[5] Tel Aviv Sourasky Med Ctr, Sourasky Med Ctr, Tel Aviv, Israel
[6] Lin Med Ctr, Haifa, Israel
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1777
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1173P
引用
收藏
页码：S941 / S941
页数：1
相关论文
共 50 条
  • [1] Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC
    Remon, Jordi
    Hendriks, Lizza E. L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 368 - 370
  • [2] Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study
    Kian, W.
    Roisman, L. C.
    Chernomordikov, E.
    Allen, A. M.
    Corn, B.
    Dudnik, E.
    Keren, S.
    Zemel, M.
    Lavrenkov, K.
    Peled, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1100 - S1100
  • [3] Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC
    Lu, Kevin
    Woodward, Brian D.
    Boys, Joshua
    Onaitis, Mark
    Husain, Hatim
    [J]. CLINICAL LUNG CANCER, 2024, 25 (01) : e58 - e61
  • [4] Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC
    Piotrowska, Zofia
    Liu, Stephen V.
    Muzikansky, Alona
    Marcoux, Nicolas
    Banwait, Mandeep
    Stevens, Sara
    Goodwin, Kelly
    Lafferty, Tracey E.
    Ackil, Jennifer
    Krueger, Elizabeth A.
    Heist, Rebecca Suk
    Lin, Jessica Jiyeong
    Gainor, Justin F.
    Hata, Aaron N.
    Shaw, Alice Tsang
    Sequist, Lecia V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Osimertinib Called "Home Run" for EGFR-Mutant NSCLC
    Rose, Suzanne
    [J]. CANCER DISCOVERY, 2020, 10 (07) : 896 - 897
  • [6] Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
    White, Maya N.
    Piotrowska, Zofia
    Stirling, Kevin
    Liu, Stephen V.
    Banwait, Mandeep K.
    Cunanan, Kristen
    Sequist, Lecia V.
    Wakelee, Heather A.
    Hausrath, Daniel
    Neal, Joel W.
    [J]. CLINICAL LUNG CANCER, 2021, 22 (03) : 201 - 209
  • [7] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
    Yang, X.
    Zhao, J.
    Liang, L.
    Xu, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
  • [8] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    [J]. ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [9] Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?
    Patil, Tejas
    Bunn, Paul A., Jr.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2204 - 2205
  • [10] A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC
    Cortiula, F.
    Naidoo, J.
    [J]. LUNG CANCER, 2023, 181
12345